Rituximab versus tocilizumab in anti-TNF inadequate responder patients with rheumatoid arthritis (R4RA): 16-week outcomes of a stratified, biopsy-driven, multicentre, open-label, phase 4 randomised controlled trial
Frances Humby, Patrick Durez, Maya H Buch et al. · The Lancet · 2021 · Randomised trial
Full textCC BY